UBS Group Issues Pessimistic Forecast for Envista (NYSE:NVST) Stock Price

Envista (NYSE:NVST - Get Free Report) had its price target lowered by analysts at UBS Group from $21.00 to $18.00 in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage currently has a "neutral" rating on the stock. UBS Group's price target would suggest a potential upside of 1.04% from the company's current price.

Several other research firms have also recently commented on NVST. Piper Sandler lowered their target price on Envista from $18.00 to $17.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. New Street Research set a $19.00 price target on shares of Envista in a research note on Thursday, March 6th. JPMorgan Chase & Co. lowered their price target on shares of Envista from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Thursday, March 6th. Jefferies Financial Group raised their price objective on shares of Envista from $20.00 to $22.00 and gave the company a "hold" rating in a report on Thursday, January 23rd. Finally, Morgan Stanley set a $16.00 target price on shares of Envista in a research note on Tuesday, April 15th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $20.08.

Envista Price Performance

NVST stock traded up $0.98 during mid-day trading on Monday, reaching $17.82. 1,608,730 shares of the company's stock were exchanged, compared to its average volume of 2,525,219. The company has a market cap of $3.02 billion, a price-to-earnings ratio of -2.75, a price-to-earnings-growth ratio of 1.27 and a beta of 0.97. Envista has a 12-month low of $14.22 and a 12-month high of $23.00. The stock's 50 day moving average is $16.52 and its 200 day moving average is $19.01. The company has a debt-to-equity ratio of 0.44, a current ratio of 2.04 and a quick ratio of 1.76.

Envista (NYSE:NVST - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.04. The business had revenue of $616.90 million for the quarter, compared to analysts' expectations of $608.17 million. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. The business's revenue for the quarter was down 1.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.26 EPS. On average, research analysts expect that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NVST. Venturi Wealth Management LLC grew its stake in shares of Envista by 528.4% during the fourth quarter. Venturi Wealth Management LLC now owns 1,948 shares of the company's stock worth $38,000 after purchasing an additional 1,638 shares during the period. UMB Bank n.a. lifted its stake in Envista by 214.4% in the first quarter. UMB Bank n.a. now owns 2,094 shares of the company's stock valued at $36,000 after acquiring an additional 1,428 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Envista by 30.5% during the 4th quarter. GAMMA Investing LLC now owns 2,304 shares of the company's stock worth $44,000 after acquiring an additional 538 shares during the last quarter. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in shares of Envista during the fourth quarter worth $53,000. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new stake in shares of Envista during the 4th quarter valued at $86,000.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.